Clinical Features Suggesting Atypical Lipomatous Tumor (ALT)
When evaluating subcutaneous lipomatous masses on ultrasound, specific clinical and imaging characteristics should immediately raise suspicion for ALT rather than benign lipoma: tumor size >10 cm, deep location below the fascia, lower extremity location, and poor tumor mobility on physical examination.
Key Clinical Discriminators
Size and Location
- Tumor diameter >10 cm is the single most important clinical predictor, present in 91.7% of ALTs versus only 51.4% of lipomas 1
- Deep-seated location (below the deep fascia) is critical—all ALTs in recent studies were subfascial, while lipomas are typically superficial 2, 1
- Lower limb predominance, particularly the thigh, is characteristic of ALT 2
- For trunk lesions, buttocks and shoulder are high-frequency ALT sites 3
Physical Examination Findings
- Poor tumor mobility on palpation distinguishes ALT from the freely mobile benign lipoma 3
- Firm consistency with elastic softness rather than the soft, doughy feel of typical lipomas 3
- Progressive enlargement over time, as ALTs tend to be larger at presentation (mean 18.7 cm vs 13.9 cm for lipomas) 4
Patient Demographics
- Age >60 years increases ALT likelihood by 2.61-fold 4
- The median age for ALT is 67 years versus 58 years for lipomas 1
Advanced Imaging Features on MRI
When ultrasound findings are uncertain and MRI is obtained, look for:
High-Specificity Features
- Thick septa (≥2 mm): Present in 58% of ALTs versus only 11.8% of lipomas 1, 5
- Multiple non-fat nodules: More than one nodule strongly suggests ALT 5
- Extensive contrast enhancement: Involvement of >1/3 of tumor volume occurs in 33.3% of ALTs versus only 2% of lipomas 1
- Nodularity, septations, and stranding on expert MRI review 2
Size Thresholds
- Tumors <8 cm with homogeneous fat signal are virtually always lipomas 5
- Tumors ≥12.8 cm with thick septa or multiple nodules are typically ALTs 5
- The diagnostic gray zone exists between 8-12 cm where biopsy becomes essential 5
Critical Clinical Pitfall
Ultrasound alone cannot reliably differentiate ALT from lipoma—it serves only as a triage tool 2. The 2025 UK guidelines explicitly state that MRI assessment cannot reliably differentiate deep lipomas from ALTs in up to 31% of cases 2.
When clinical suspicion exists based on the above features, proceed directly to core needle biopsy with MDM2 amplification testing by fluorescence in-situ hybridization—this is the definitive diagnostic test that will alter surgical approach 2.
Practical Algorithm
- Immediate ALT suspicion if ANY of: subfascial location, size >10 cm, lower extremity, poor mobility, age >60
- Obtain MRI if ultrasound uncertain or shows concerning features
- Proceed to biopsy with MDM2 testing if: deep location + size >8 cm, OR septa ≥2 mm, OR multiple nodules, OR extensive enhancement
- Reassure and observe only if: superficial, <8 cm, homogeneous fat signal, freely mobile
The absence of B symptoms is expected and uninformative, as ALTs are biologically indolent with virtually no metastatic capacity in extremity locations 2.